Research on antibodies and their uses. Covers engineered antitoxin antibodies, long-lasting immunity, monoclonal therapies, and antiviral T cells.
Researchers found that camel antibodies protected uninfected mice from MERS and helped infected mice expunge the disease. The study suggests these antibodies might be therapeutic for MERS patients and protect uninfected household members and healthcare workers.
Researchers at CRT and Bioinvent are developing antibodies targeting OX40 and 4-1BB, 'co-receptors' that stimulate killer T-cells. The goal is to reverse tumour cell suppression of immune responses, allowing the immune system to fight cancer.
Researchers at NYU College of Dentistry are working with Rheonix, Inc. on a Phase II grant to develop an affordable point-of-care test for HIV/AIDS detection in remote areas. The test aims to detect both antibodies and viral RNA in a single specimen within under one hour.
A multivalent vaccine candidate induced broad antibody responses in trial participants, including to non-vaccine strains, suggesting a possible solution to evading immunity. The study provides evidence that VLP-based vaccines may overcome antigenic drift, but further development and clinical trials are needed for a vaccine suitable for...
Researchers report significant recovery after a single dose of an experimental treatment targeting interleukin-23, a key immune signaling protein in psoriasis. The study found nearly all patients experienced dramatic improvement in their symptoms, with an average 80% reduction in skin lesions.
Researchers have successfully treated dogs with hemophilia using a mutant human protein with unusually high blood-clotting power. The treatment eliminated pre-existing antibodies and reversed the bleeding disorder in two years without causing thrombosis or immune reactions.
Researchers found increased pocket depth and clinical attachment loss in patients with rheumatoid arthritis, highlighting the link between gum disease and joint inflammation. The study also identified Porphyromonas gingivalis antibodies as biomarkers for identifying patients who may benefit from periodontal treatment.
Recent research suggests that irisin, believed to travel from muscle to fat tissue after exercise, may not exist in humans. New tests used in previous studies found antibodies were poorly vetted and nonspecific, leading to false positive results.
A new study has identified antibodies targeting dopamine D2 receptors and NMDA glutamate receptors in children experiencing their first episode of psychosis. This finding suggests that autoimmunity may play a role in the development of psychosis, offering hope for new treatment approaches.
A new study suggests that adults over 30 only get the flu about twice a decade, according to researchers who analyzed blood samples from volunteers in Southern China. The study found that flu-like illnesses can be caused by many pathogens, making it difficult to assess infection frequency.
Researchers have developed an antibody called FcDART that provides 100% protection against the H5N1 influenza virus in ferrets and mice. This breakthrough could lead to the development of vaccines to match each flu virus and protect vulnerable populations.
A collaborative team identified mechanisms involved in antibody response to the Marburg virus by studying a survivor's blood. The study reveals that the human immune system can effectively fight Marburg virus infections by producing antibodies.
Human antibodies have been isolated and characterized that can neutralize the Marburg virus, a close cousin to Ebola. The discovery could lead to the development of an effective treatment and vaccine against these often lethal viruses. Researchers hope to complete clinical safety trials by the end of the year.
A Scripps Research Institute team has discovered an antibody that can target both Marburg and Ebola viruses, paving the way for new treatment options. The antibody works by binding to a vulnerable site on the virus's surface, preventing it from entering human cells.
Researchers found that certain bacterial DNA can be passed from mother to child, affecting traits such as immunity and inflammation. This discovery suggests a new factor in understanding how genes influence illness and health.
Scientists at NTU Singapore have developed an antibody that boosts survival chances for patients with influenza and pneumonia. The antibody, proven effective in lab tests, can also be used to develop a diagnostic kit to track treatment effectiveness.
George Mason University researchers have discovered peptides in alligator blood that can effectively fight bacterial infections. These peptides, part of the innate immunity system, could potentially be developed into new treatments for wound infections and biothreat agents.
Researchers fuse human hormones with cow antibodies to create long-lasting treatment options for hormone deficiencies and other diseases. The new therapy shows promise in reducing the frequency of injections needed for conditions like Turner syndrome and low birth weight.
A new TSRI study explains how booster shots prompt immune memory to improve, a crucial step toward longer-lasting vaccines. The research demonstrates how immune cells evolve and adapt to recognize viruses, leading to more diverse and effective antibody responses.
Researchers at Caltech develop antibody-based molecules that bind to and neutralize HIV more effectively than natural antibodies, offering a potential approach to engineer more effective HIV-fighting drugs. The breakthrough uses DNA as a molecular ruler to design novel molecules.
Researchers at Aarhus University have discovered ten new antibodies that can inhibit blood vessel formation near tumors, cutting off oxygen and nutrient supply. The antibodies appear to work effectively in laboratory tests and show promising therapeutic potential.
Researchers at NYU Polytechnic School of Engineering have developed a new colloidal gold test strip that demonstrates high detection sensitivity for cardiac troponin I (cTn-I) detection. The new strip uses microplasma-generated gold nanoparticles, attracting more antibodies and resulting in significantly higher detection sensitivity.
Researchers at McMaster University have discovered a new class of antibodies that can neutralize a wide range of influenza A viruses, paving the way for a universal flu vaccine. The vaccine would only need to be given once and could protect against all strains of flu, even when the virus mutates.
Researchers at TSRI have developed a more effective nicotine vaccine by targeting only the left-handed version of nicotine, eliciting four times as many antibodies. The new vaccine has shown promise in animal studies and could lead to treatments for smoking addiction.
Researchers at University of Cincinnati discover a new drug therapy that effectively lowers antibodies in kidney patients, paving the way for more successful kidney transplants. The study suggests this approach could benefit up to 10-20% of heart and pancreas transplant candidates who are currently ineligible due to high antibody levels.
Researchers found that endogenous retroviruses play a critical role in the body's immune defense against common bacterial and viral pathogens. The ERV DNA can activate B cells to produce protective antibodies, suggesting that these viruses have an 'physiological' function.
Researchers at Yale University have developed synthetic antibody mimics (SyAMs) that target disease cells and stimulate immune responses, offering potential for treating prostate cancer and other diseases.
Researchers at the University of Southampton have found that a specific form of antibody, IgG2B, is more effective at stimulating cancer immunity than others. By engineering antibodies into a locked B structure, they aim to create stronger immune stimulators for cancer patients.
A study found that seasonal flu vaccines protect against multiple flu strains, including those not included in vaccine formulations. The researchers also discovered that exposure to birds can elicit immune responses to avian influenza viruses in humans.
A study found that seasonal flu vaccines can induce strong immune responses against multiple flu virus subtypes, including some not included in vaccine formulations. This could provide protection against emerging pandemic strains from avian populations.
Research team led by Miguel Soares discovered that specific bacterial components in the human gut microbiota can trigger a natural defense mechanism against malaria. High levels of circulating anti-alpha-gal antibodies induced by vaccination are highly protective against malaria transmission.
Ramy Arnaout has been awarded a two-year grant to analyze antibody repertoires of over 1,000 Americans to clarify the link between antibodies, cardiovascular disease, and aging. The goal is to determine individual treatment needs for patients with cardiovascular disease.
A team of researchers from the University of Surrey has identified a rogue protein in multiple sclerosis, which attacks the body's central nervous system. The discovery could lead to a better understanding of the disease and new treatments against neurodegenerative diseases.
Patients with a history of heparin-induced thrombocytopenia (HIT) may be ready for urgent heart surgery sooner than previously thought, according to new research. A combination of appropriate blood screenings and therapeutic plasma exchange can help lower HIT antibody levels quickly.
Researchers found that therapeutic plasma exchange can rapidly reduce HIT antibody levels, making patients eligible for urgent cardiac surgery sooner. The study suggests using both functional and immunoassays to determine patient readiness, with the functional assay indicating lower antibody levels more quickly.
Researchers at Scripps Research Institute have identified vulnerable sites on the surface of Ebola virus that are targeted by the antibodies in ZMapp, a drug cocktail administered to patients during the 2014 outbreak. The study provides insights into how ZMapp works and suggests strategies to improve it.
Researchers developed a system to identify high-affinity nanobodies, which can precisely target specific molecules. This allows scientists to select the best nanobodies, eliminate cross-reactive ones, and generate super-high-affinity dimers for therapeutic or diagnostic applications.
A new single-domain antibody called FC5 has proven able to cross the blood-brain barrier, opening doors to new treatments for brain diseases. This breakthrough technology allows for the delivery of larger molecules into the brain, targeting conditions such as Alzheimer's, Parkinson's, and cancer.
A study found that Staphylococcus aureus uses protein A as a superantigen to activate many B cells, leading to immune tunnel vision and reduced protection against infection. This knowledge can inform future vaccine approaches to combat MRSA.
Researchers identify a bacterial protein that mimics the satiety hormone, leading to variations in food intake. A blood test for this protein could lead to specific treatments for eating disorders, while neutralizing the protein may prevent dysregulation of food intake.
A new blood test has been identified as a potential predictor for focal segmental glomerulosclerosis (FSGS), a devastating form of kidney disease. The test, called FAST, uses high-density protein tests to detect antibodies against specific antigens that are significantly increased in patients at risk for FSGS.
Researchers have successfully delivered antibody mimics into cells using a disarmed version of anthrax toxin, offering a potential new approach for treating various diseases. The development demonstrates the first effective delivery of antibodies into cells, which could lead to novel drug treatments.
Kidney transplant recipients infected with BK virus are more likely to develop donor-specific antibodies, which can lead to organ rejection. The study found a significant association between persistent BK infections and the development of these detrimental antibodies.
Researchers at Caltech have developed a new technique called vectored immunoprophylaxis (VIP) to prevent the spread of diseases like HIV, malaria, and influenza. This method provides specific antibodies that can neutralize pathogens, offering a potential solution for widespread use in the less developed world.
A new study reveals that gut microbes play a vital role in stimulating protective immune responses to the seasonal flu vaccine. Researchers found that mice with altered gut microbiota showed reduced antibody responses to vaccination, highlighting the importance of gut microbes in vaccine efficacy.
A new study uses genetically modified plants to teach the immune system to tolerate clotting factors, reducing the risk of antibody formation. The treatment, which involves feeding mice with plant capsules, has shown promising results and may offer a cost-effective alternative to current treatments.
Scientists from A*STAR's Bioprocessing Technology Institute uncover crucial role of DOK3 and SHP1 in plasma cell development and production. This discovery advances understanding of plasma cells and antibody response, potentially leading to improved treatment for patients with autoimmune diseases like lupus and multiple myeloma.
Researchers develop a potential therapy for Sudan ebolavirus, showing promising results in laboratory tests and mouse models. The humanized antibody has been identified as an immunotherapeutic candidate to treat SUDV infection.
Researchers at MIPT and RAS made a significant step towards creating medical nanorobots by enabling nanoparticles to produce logical calculations. The discovery paves the way for biomedical technologies, including selective binding to target cells and analyzing biological materials.
A study led by Johns Hopkins Medicine found that at least one in 10 inner-city children has a food allergy, with peanuts being the most common allergen. The study also suggests that early-life exposure to certain microbes may play a protective role against food allergies.
A new study by Johns Hopkins Medicine found that nearly one in ten inner-city children has a food allergy, with breastfed kids and high exposure to endotoxin being potential risk factors. The study also highlighted a subgroup of children with higher-than-average allergy risk.
A new virus-like particle vaccine has shown promising results in a human trial, generating antibodies that provide long-term protection against chikungunya. The vaccine, composed of non-infectious VLP particles, was well-tolerated and effective across different doses.
Researchers found that the HIV virus's outer envelope is mistaken for bacterial antigens by the immune system, leading to ineffective antibodies. The study suggests a new hypothesis for how HIV vaccine development could be improved by targeting the gut flora.
Researchers at Johns Hopkins Bloomberg School of Public Health have found a potential new path toward malaria immunization by injecting a vaccine-like compound into mice. The approach, known as Vector Immunoprophylaxis (VIP), triggers the creation of antibodies that prevent malaria in 70% of mice.
Researchers discovered that a specific type of IgG2 antibody protects Pseudomonas aeruginosa by binding to extra-long sugars on the bacterial surface. This protection can lead to reduced antibacterial capacity and worsened disease outcomes in immunized individuals.
Ashley Anh Vo, a transplant pharmacist at Cedars-Sinai, received the 2014 Clinician of Distinction award for her work on anti-rejection drugs. Her research identified IVIG as an effective therapy to reduce HLA antibody levels and prolong patient survival.
Researchers discovered new vaccine targets that could help combat malaria by identifying previously untested antigens and gaining insights into antigen combination. A group of infected children was followed over six months to identify combinations of antibodies providing up to 100% protection against clinical episodes.
Aarhus University researchers have created an easier method to tag proteins with DNA, enhancing diagnostic techniques, nanotechnology, and disease treatment. The new method allows for controlled conjugation of macromolecules, making it possible to attach chemotherapeutics to antibodies while preserving their recognition element.
A potential biomarker associated with participants who experienced a more profound viral load reduction after receiving the vaccine has been identified. The biomarker, anti-C5/gp41732-744 antibody levels above 4μg/ml, may be able to predict which patients will benefit most from the therapeutic HIV vaccine candidate Vacc-4x.
A new anti-EGFR antibody has been successfully tested on canine cancer cells, offering a promising approach to diagnosis and treatment. The antibody, developed from its human counterpart, demonstrates high specificity and is expected to improve cancer treatment outcomes for dogs.